There was also a markedly large difference in MYL5 expression levels between pan-cancer and normal tissues, where distant recurrence-free survival, post-progression survival, relapse-free survival, distant metastasis-free survival, and OS of patients with breast cancer were longer and had better odds with high expression of MYL5 compared with lower expression [35]. Here, MYL5 is linked to breast carcinoma.